Nektar Therapeutics Initiates Clinical Study of NKTR358 a FirstinClass Regulatory T Cell Stimulator Being Developed for the Treatment of Immune and Inflammatory Disorders

SAN FRANCISCO March 27 2017 PRNewswire Nektar Therapeutics NASDAQ NKTR today announced that it has begun dosing in a Phase 1 clinical study evaluating NKTR358 the company's new biologic therapy which is being developed to treat a wide range of autoimmune ...